Small cell lung cancer is an aggressive, rapidly growing subtype of lung cancer that tends to metastasize early. It is biologically and clinically distinct from non-small cell lung cancer.
Soft tissue sarcoma pipeline activity includes 70+ companies and 75+ therapies. A phase II ADI-PEG 20 trial with gemcitabine and docetaxel was designed for sarcomas, while other 2026 studies span synovial sarcoma and unresectable advanced disease.
Ascentage Pharma said six clinical abstracts were selected for ASCO 2026 and four preclinical studies will be presented at AACR 2026. The presentations feature olverembatinib and other pipeline candidates.
Barclays initiated Amgen with an Equal Weight rating and a $185 price target as debate over the Phase 3 MARITIME trial continued. Amgen said 2025 revenue and earnings per share rose by double digits.
Researchers identified three distinct molecular phenotypes of small cell lung cancer that could help stratify patients for targeted therapy. Only patients with ANXA1Low infiltrated phenotype derived significant survival benefit from chemotherapy plus immune checkpoint inhibitors. Separate research found that targeting epigenetic regulators like PRC2 and G9a/GLP could enhance treatment efficacy.
GSK's antibody-drug conjugate risvutatug rezetecan has received Orphan Drug Designation in Japan for small-cell lung cancer, marking its sixth global regulatory designation. The decision was based on phase I trial data showing durable responses in extensive-stage SCLC patients. The drug is currently in phase III development for relapsed ES-SCLC.
Two recent clinical trials found that adding immunotherapy to standard chemoradiation did not improve survival for patients with limited-stage small-cell lung cancer or high-risk HPV-positive oropharyngeal cancer, though both studies revealed important insights about treatment delivery and radiation scheduling.
IDEAYA Biosciences announced Q4 2025 financial results with $1.05 billion in cash reserves and confirmed 130 progression-free survival events in its Phase 2/3 OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with topline results expected by late March 2026.
Scientists at three institutions have developed distinct nanoparticle-based drug delivery systems designed to target cancer tumors more precisely while reducing side effects, with approaches ranging from DNA nanomachines to transformable nanofibers.
Amgen shares have climbed 35% over six months, trading near $388, as analysts raise price targets following strong fourth-quarter 2025 results and expanding oncology pipeline programs including IMDELLTRA and LUMAKRAS.
T-cell immunotherapies including CAR T-cell therapy and T-cell engagers are expanding cancer treatment options but present significant cardiovascular risks and operational complexities requiring coordinated multidisciplinary management.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07559929 |
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung CancerInhibitors or Platinum-Based Agents for Small Cell Lung Cancer. |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07557225 |
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors |
RECRUITING | NA |
| NCT07551635 |
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07550049 |
Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology |
NOT_YET_RECRUITING | |
| NCT07547332 |
Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07531095 |
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) |
RECRUITING | PHASE1 |
| NCT07508852 |
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT07489339 |
MDT-Based Nursing for Small Cell Lung Cancer During Chemo-Immunotherapy |
COMPLETED | NA |
| NCT07476287 |
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer |
RECRUITING | PHASE2 |
| NCT07472647 |
SYS6090 Combination Therapy in Advanced Lung Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
